Sunvozertinib outperformed chemotherapy as first-line treatment for advanced non–small-cell lung cancer with EGFR exon 20 insertions in a Phase 3 trial. In NEJM data (published May 29, 2026), median progression-free survival was 10.3 months with sunvozertinib versus 7.5 months with carboplatin–pemetrexed based on blinded independent central review. Across 324 randomized patients, sunvozertinib also produced higher objective response rates (58.9% vs 31.1%) and longer duration of response (11.2 vs 7.1 months). Grade 3 or higher adverse events were more frequent on sunvozertinib (75.5%) than on chemotherapy (56.7%), with no deaths attributed to investigator-assessed drug-related adverse events. The study is backed by Dizal Pharmaceuticals (NCT05668988), and the investigators reported overall survival data as immature at the time of analysis.